ISRCTN12371179已完成1 期
A two-part study to evaluate the safety, pharmacokinetics, pharmacodynamics of HTL0009936 in healthy elderly and elderly with below average cognitive functioning.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 65+ years
- •2. Blood pressure =140/90 mmHg at screening
- •3. Heart rate between 45 and 100 bpm at screening
排除标准
- •1. Use of antihypertensive drugs prior to and during the study period
- •2. Consumption of alcohol and caffeine-containing products, use of nicotine-containing products, and use of drugs influencing CYP3A4 and CYP2D6 activity prior to and during the study
- •3. Poor or ultra-rapid CYP2D6 metabolizer discovered on genotype screening
研究者
相似试验
已完成
不适用
A two-part study to evaluate the safety, pharmacokinetics, pharmacodynamics of HTL0009936 in healthy elderly and elderly with below average cognitive functioning.10057167dementiaAlzheimer's diseaseNL-OMON42111Heptares Therapeutics Ltd.42
已完成
2 期
A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington*s Disease.Early Stage Huntingtons Disease10028037NL-OMON45299Stealth Bio Therapeutics Inc24
进行中（未招募）
1 期
A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease.EUCTR2016-003730-25-NLStealth Bio Therapeutics Inc24
进行中（未招募）
1 期
A two-part study to investigate the safety and preliminary efficacy of Givinostat in patients with Polycythemia VeraJAK2V617F positive Polycythemia VeraMedDRA version: 19.0Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2013-000860-27-PLITALFARMACO S.p.A52
进行中（未招募）
1 期
A two-part study to investigate the safety and preliminary efficacy of Givinostat in patients with Polycythemia VeraJAK2V617F positive Polycythemia VeraMedDRA version: 18.0 Level: LLT Classification code 10036061 Term: Polycythemia vera System Organ Class: 100000004864EUCTR2013-000860-27-GBITALFARMACO S.p.A48